These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 27384848)

  • 1. [Gene-modified T-cell therapy using chimeric antigen receptors for pediatric hematologic malignancies].
    Nakazawa Y
    Rinsho Ketsueki; 2016 Jun; 57(6):701-8. PubMed ID: 27384848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chimeric antigen receptor T-cell therapy for hematological malignancies].
    Nakazawa Y
    Rinsho Ketsueki; 2019; 60(9):1351-1357. PubMed ID: 31597863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current Status and Challenges of CAR-T Immunotherapy in Hematologic Malignancies -Review].
    Cheng X; Wang YJ; Feng S; Wu YY; Yang TH; Lai X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):626-630. PubMed ID: 29665944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Advances in immunotherapy of hematological malignancies by using chimeric antigen receptor-modified lymphocytes].
    Xu XJ; Zhao HZ; Tang YM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):521-5. PubMed ID: 23628068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.
    Long AH; Haso WM; Shern JF; Wanhainen KM; Murgai M; Ingaramo M; Smith JP; Walker AJ; Kohler ME; Venkateshwara VR; Kaplan RN; Patterson GH; Fry TJ; Orentas RJ; Mackall CL
    Nat Med; 2015 Jun; 21(6):581-90. PubMed ID: 25939063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
    Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
    Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric Antigen Receptor T Cell Therapy Targeting CD19-Positive Leukemia and Lymphoma in the Context of Stem Cell Transplantation.
    Schubert ML; Hückelhoven A; Hoffmann JM; Schmitt A; Wuchter P; Sellner L; Hofmann S; Ho AD; Dreger P; Schmitt M
    Hum Gene Ther; 2016 Oct; 27(10):758-771. PubMed ID: 27479233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies.
    Gill S; June CH
    Immunol Rev; 2015 Jan; 263(1):68-89. PubMed ID: 25510272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells.
    Allegra A; Innao V; Gerace D; Vaddinelli D; Musolino C
    Blood Cells Mol Dis; 2016 Nov; 62():49-63. PubMed ID: 27865176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts.
    Bishop DC; Xu N; Tse B; O'Brien TA; Gottlieb DJ; Dolnikov A; Micklethwaite KP
    Mol Ther; 2018 Aug; 26(8):1883-1895. PubMed ID: 29861327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?
    Pegram HJ; Smith EL; Rafiq S; Brentjens RJ
    Immunotherapy; 2015; 7(5):545-61. PubMed ID: 26065479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success.
    Long KB; Young RM; Boesteanu AC; Davis MM; Melenhorst JJ; Lacey SF; DeGaramo DA; Levine BL; Fraietta JA
    Front Immunol; 2018; 9():2740. PubMed ID: 30559740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematologic Malignancies: Plasma Cell Disorders.
    Dhodapkar MV; Borrello I; Cohen AD; Stadtmauer EA
    Am Soc Clin Oncol Educ Book; 2017; 37():561-568. PubMed ID: 28561703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy.
    Firor AE; Jares A; Ma Y
    Exp Biol Med (Maywood); 2015 Aug; 240(8):1087-98. PubMed ID: 25956686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies.
    Nagle SJ; Garfall AL; Stadtmauer EA
    Cancer J; 2016; 22(1):27-33. PubMed ID: 26841014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Tol2 transposon system mediates the genetic engineering of T-cells with CD19-specific chimeric antigen receptors for B-cell malignancies.
    Tsukahara T; Iwase N; Kawakami K; Iwasaki M; Yamamoto C; Ohmine K; Uchibori R; Teruya T; Ido H; Saga Y; Urabe M; Mizukami H; Kume A; Nakamura M; Brentjens R; Ozawa K
    Gene Ther; 2015 Feb; 22(2):209-15. PubMed ID: 25427612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities.
    Ho M; Zanwar S; Paludo J
    Eur J Haematol; 2024 Feb; 112(2):197-210. PubMed ID: 37545132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies.
    Sabatino M; Hu J; Sommariva M; Gautam S; Fellowes V; Hocker JD; Dougherty S; Qin H; Klebanoff CA; Fry TJ; Gress RE; Kochenderfer JN; Stroncek DF; Ji Y; Gattinoni L
    Blood; 2016 Jul; 128(4):519-28. PubMed ID: 27226436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
    Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
    Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
    Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
    Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.